You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

446 Results
Document
Mar 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
New Drug Funding Program
    Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daratumumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Blog post
The first time Lauri P. met with her fellow patient and family advisors at Cancer Care Ontario, she was unprepared for the emotions stirred up by the...
Mar 2019
Guidelines and Advice
Status: In-Review
ID: GL 6-A-2018-1
Mar 2019
Blog post
Jane Smart, Senior Specialist, Technical Training, Legal and Privacy, CCO, shares her unique perspectives of cancer as a patient and as a parent....
Apr 2019
Document
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
iMAtinib,
vinCRIStine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Document
May 2019
Document
Sep 2019
Document
Oct 2019

Pages